Amerise BioScie (531681)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me look at Amerise BioScie with Graham's discipline. At ₹0.70, the stock trades below book value of ₹0.93 — a P/B of 0.75. That caught my eye. But a cheap price is only a starting point. The company earns a miserable return: ROE is 1.25% and ROCE is 0.19%. Every hundred rupees of equity produces just over a rupee of profit. As a business, it is not earning its keep; with no dividend, I get no return while waiting. Sales growth is exactly 0.00%, and the latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr. The 150% profit growth and PEG of 0.44 look enticing only if you ignore that the base is tiny and the top line is flat. At P/E of 66, I am paying 66 times a fragile profit stream. The Piotroski F-score of 6/9 is modestly encouraging, but with promoter holding N/A and debt/equity N/A, there is not enough transparency to satisfy Mr. Graham. Market cap is just ₹5 Cr — a microcap with liquidity risk. A below-book price gives some asset support, but book value must eventually be converted into earnings, dividends, or cash from a liquidation. Right now, neither the operating engine nor the capital allocation justifies a purchase. I might watch this as an asset play, but the margin of safety is solely in the balance sheet, not in earning power. I would demand years of clean financials, proof that the zero-quarter is an anomaly, and evidence of returning capital before I act.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer